Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01276691 · ClinicalTrials.gov registry record · Phase 4
Effect of Aspirin on Hemostatic and Vascular Function After Live Fire Fighting
A Phase 4 study of Cardiovascular Risk Factor and C.Medical Procedure; Vascular, Functional or Late, sponsored by University of Illinois at Urbana-Champaign.
- Completed
- Registry status
- Phase 4
- Development phase
- 24
- Enrollment target
- 1
- Study location
NCT01276691 is a Phase 4 study of Cardiovascular Risk Factor and C.Medical Procedure; Vascular, Functional or Late that has completed, run by University of Illinois at Urbana-Champaign. The registered enrollment target is 24 participants, below the 3,067-participant average among 31 other Cardiovascular Risk Factor trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01276691, a Phase 4 study of Cardiovascular Risk Factor and C.Medical Procedure; Vascular, Functional or Late, has completed, sponsored by University of Illinois at Urbana-Champaign.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 24 participants
- Enrollment target
- 1
- Study location
Study Summary
The investigators hypothesize that 1. an acute treatment of low-dose aspirin will lead to a) decreased resting platelet activation, platelet aggregation, and clotting potential, b) increased fibrinolytic potential following fire fighting, c) no significant effect on endothelial function or arterial stiffness versus the placebo condition. 2. chronic treatment with low-dose aspirin will lead to a) decreased resting and fire fighting induced platelet activation, platelet aggregation, clotting potential, b) increased fibrinolytic potential, and c) increased endothelial function and decreased arterial stiffness in response to live fire fighting versus the placebo condition. 3. short-term fire fighting activity will result in: a) a reduction in arterial function (reduced endothelial function, increased augmentation index and an attenuated arterial stiffness response); b) a disruption in hemostasis that is characterized by an increase in platelet number and function, an increased coagulatory potential and altered fibrinolytic potential; and c) an elevation in procoagulatory cytokines, systemic inflammation, monokine chemoattractant protein, and matrix metalloproteinases.
Conditions Studied
Interventions
- DRUG 81 mg enteric coated aspirin
Study Locations (1)
Illinois
- Illinois Fire Service Institute - Champaign
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2011-02 |
| Est. Completion | 2012-12 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01276691
The ClinicalTrials.gov registry entry for NCT01276691 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,067-participant average among 31 other Cardiovascular Risk Factor trials with a reported enrollment target (99% lower). The listed sponsor is University of Illinois at Urbana-Champaign, which has 129 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Cardiovascular Risk Factor appearing as the primary indexed condition, and to 1 intervention - of which 81 mg enteric coated aspirin is the first listed.
NCT01276691 reports 1 study location spanning 1 distinct geographic area - top geographies include Illinois.
Frequently Asked Questions
What is clinical trial NCT01276691 about?
NCT01276691 is a clinical study titled "Effect of Aspirin on Hemostatic and Vascular Function After Live Fire Fighting". The investigators hypothesize that 1. an acute treatment of low-dose aspirin will lead to a) decreased resting platelet activation, platelet aggregation, and clotting potential, b) increased fibrinolytic potential following fire fighting, c) no significant effect on endothelial function or arterial...
What is the current status of trial NCT01276691?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 24 participants. The study started on 2011-02. Estimated completion is 2012-12.
What conditions does trial NCT01276691 study?
This clinical trial studies the following conditions: Cardiovascular Risk Factor, C.Medical Procedure; Vascular, Functional or Late, Electrolyte and Fluid Balance Conditions.
What interventions are being tested in trial NCT01276691?
The interventions under investigation include: 81 mg enteric coated aspirin (DRUG).
Who is sponsoring clinical trial NCT01276691?
This trial is sponsored by University of Illinois at Urbana-Champaign, which has 129 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01276691 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cardiovascular Risk Factor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Gut Flora Metabolite Reduction After Dietary Intervention (GRADY)
RECRUITING · NA
-
Community Benefit of No-charge Calcium Score Screening Program
RECRUITING
-
Biomechanical Precision Medicine Registry for Patients With and Without Heart Failure
RECRUITING
-
The Influence of Mitochondrial-Derived Reactive Oxygen Species on Racial Disparities in Neurovascular Function
RECRUITING · NA
-
Sleep Duration and Cardiovascular Health
RECRUITING · NA
-
The Potassium Supplementation Study
RECRUITING · NA
Explore more on PlainTrial
Cardiovascular Risk Factor
All registered trials for this condition
C.Medical Procedure; Vascular, Functional or Late
All registered trials for this condition
Illinois
All trials with a study site in Illinois
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.